Another study has revealed that the R-2HG/FTO axis exhibits the glycolytic inhibitory function, suggesting that R-2HG and specific FTO inhibitors, alone or in combination with other anticancer agents, provide new treatment options for AML therapy by targeting tumor metabolism and epigenetic modulation (Qing et al., 2021). The gene discussed is FTO; the disease is acute myeloid leukemia.